phytotherapy

Ashwagandha — the common name for the plant Withania somnifera — has one of the longest continuous histories of use of any medicinal plant. Its story begins in the Indian subcontinent, where the herb appears repeatedly in the classical Ayurvedic pharmacopeia as a tonic and “rasāyana” (rejuvenator). Ancient Ayurvedic texts such as the Charaka Saṃhitā and Sushruta Saṃhitā (themselves compilations and redactions of material that crystallized in the first centuries BCE–CE and later) recommend the root for strength, vitality, and for conditions now described as debility, nervous exhaustion and sexual dysfunction; traditional Sanskrit names — most famously “ashwagandha” (literally “horse-smell,” referring to the root’s aroma and the plant’s traditional attribution of conferring the strength of a horse) — reflect those uses. Modern reviews of Ayurvedic sources and ethnomedicine summarize these longstanding uses and quote the classical texts as their origin. (PMC)

Outside the Indian tradition the plant (or very similar “nightshade” herbs) was known in other old medical systems. Scholars have identified plants of the Withania/Solanaceae group in Greco-Roman herbal listings and in later Unani and folk traditions across North Africa and the Mediterranean; in short, the use of Withania-type plants for weakness, inflammation and postpartum care is attested beyond India long before modern botany formalized the species. (ahpa.org)

The transition from traditional medicine to botanical science began in the 18th century. In 1753 Carl Linnaeus described the plant under a different genus name (he recorded it as Physalis somnifera in his Species Plantarum), and later botanical work consolidated it under the genus Withania (the conserved name honors the early-19th-century English figure Henry Witham). By the 19th and early 20th centuries European and colonial botanists were recording its distribution across India, Nepal, Sri Lanka and parts of Africa and the Middle East, and herbarium specimens and pharmacopoeias began treating it as a discrete, identifiable species: Withania somnifera (L.) Dunal. (pza.sanbi.org)

Modern phytochemistry and pharmacology accelerated in the mid-20th century. Chemists isolated and characterized the plant’s distinctive steroidal lactones — the withanolides — that are now widely regarded as the main bioactive family in the species. The first withanolide to be isolated and described in the literature — withaferin A — was reported by Lavie and Yarden in 1962; since then hundreds of related withanolides and other constituents (alkaloids, sitoindosides, etc.) have been identified and studied for their biochemical activities. That chemical work changed ashwagandha from a vague “tonic” in Western eyes into a plant with definable molecules to test in laboratories. (RSC Publishing)

Laboratory and animal studies through the late 20th century produced a long list of possible mechanisms — anti-inflammatory, anti-oxidant, modulation of the hypothalamic–pituitary–adrenal (HPA) axis, neuroprotective and even anticancer actions — and those preclinical leads prompted the first controlled human studies in the 2000s and 2010s. Several early randomized, double-blind, placebo-controlled trials became touchstones for modern clinical interest. For example, a widely cited 2012 randomized, double-blind, placebo-controlled trial by Chandrasekhar and colleagues tested a high-concentration, full-spectrum root extract and reported significant reductions in perceived stress and serum cortisol versus placebo. Subsequent randomized trials explored related indications: a 2013 pilot study by Ambiye and colleagues examined spermatogenic effects in oligospermic men and reported large improvements in sperm count and motility after 90 days; a 2015 randomized trial by Wankhede et al. reported increases in muscle strength and mass and a rise in serum testosterone in healthy men undertaking resistance training; and several 2017–2019 trials (for example by Choudhary et al. and Lopresti et al.) examined cognitive function, insomnia, and anxiety with generally favorable results in small-to-moderate sized populations. These clinical studies gave the first controlled human evidence that some classical claims (stress-reduction, improvements in certain reproductive and performance parameters, sleep and cognition) could be measured in trials — while also revealing the need for larger, higher-quality studies. (PMC)

As trials accumulated, systematic reviews and meta-analyses began to appear. Over the last decade reviewers have pooled randomized trials for stress/anxiety and for sleep and reported statistically significant effects in pooled analyses, tempered by caveats about study quality, small sample sizes, heterogeneity of extracts and doses, and short follow-up periods. Government and public-health bodies have taken notice: the U.S. National Institutes of Health’s Office of Dietary Supplements now maintains an updated “Health Professional Fact Sheet” summarizing the evidence, typical doses used in trials (commonly 300–600 mg/day of standardized root extract), and known safety considerations (possible gastrointestinal side effects, sedation in some people, interactions and rare reports of liver injury), while emphasizing that the overall evidence base is still developing. (ScienceDirect)

In the last five to ten years the pace of research and commercialization has only accelerated. Dozens of randomized controlled trials, several larger meta-analyses, and a wave of nutraceutical products standardized for total withanolides have appeared; investigators are exploring formulations for mood and sleep, for sports performance and recovery, for male fertility, and as adjuvants in metabolic and neurodegenerative research. At the same time pharmacologists continue to study withanolides (including withaferin A) in cell and animal models for anti-inflammatory, immunomodulatory and anticancer effects — work that has generated potential drug leads but not yet clinical approvals for those indications. Regulatory and safety authorities now advise caution about product quality (variability between commercial extracts), dose, and contraindications (for example pregnancy, certain autoimmune or hormone-sensitive conditions). (MDPI)

Summing up: ashwagandha’s arc runs from an ancient Ayurvedic “rejuvenator” noted in millennia-old Indian medical texts through botanical classification in the 18th–19th centuries, to chemical discovery in the 1960s (withaferin A) and a modern clinical literature that began to solidify in the 2000s and 2010s with randomized human trials and meta-analyses. The plant’s traditional profile — an adaptogen used for weakness, stress and reproductive health — largely guided modern research questions, and clinical science has begun to corroborate some of those traditional uses while also introducing new, evidence-based caveats about dosing, standardization and safety. For readers interested in primary sources, good starting points are reviews of classical Ayurvedic references and ethnobotany, the 1962 chemical description of withaferin A, the 2012 Chandrasekhar randomized trial on stress, and the recent NIH Office of Dietary Supplements fact sheet summarizing contemporary clinical evidence and safety considerations. (PMC)

(Source : ChatGPT)

Ashwagandha (Withania somnifera) can reduce inflammation because it contains natural compounds called withanolides, the most studied of which is withaferin A. These molecules interact with several of the same biochemical “switches” the body uses to start and sustain inflammation, and by calming those switches Ashwagandha helps lower the overall inflammatory response.

Inflammation itself is the body’s normal reaction to injury or infection: immune cells release signaling molecules called cytokines (for example TNF-α, IL-6 and IL-1β) and activate signaling pathways that produce redness, swelling and pain. Those reactions are useful for short periods, but when they remain active for a long time they can harm tissues and contribute to chronic disease. Ashwagandha’s compounds work at multiple points in this process to reduce both the signals and the biochemical traffic that keep inflammation going.

One important target is a protein complex known as NF-κB, which acts like a master switch for many inflammatory genes. Withanolides, including withaferin A, have been shown in laboratory studies to interfere with NF-κB activation; when that master switch is less active, cells produce fewer inflammatory chemicals. Ashwagandha also affects other signaling routes that amplify inflammation, such as MAPK pathways, so the overall amplification of the inflammatory response is reduced.

Beyond switching off signaling pathways, Ashwagandha tends to lower levels of key inflammatory molecules. In experimental studies it has been associated with decreases in cytokines like TNF-α, IL-6 and IL-1β, which are commonly elevated in chronic inflammation. The plant’s extracts have also been shown to reduce the activity of enzymes that make inflammatory mediators—specifically COX-2, which helps produce prostaglandins that cause pain and swelling, and iNOS, which produces nitric oxide that can worsen inflammation. By cutting activity at these enzymes, fewer inflammatory chemicals are produced at the tissue level.

Inflammation and oxidative stress feed each other, and Ashwagandha appears to help on that front as well. Some components activate the Nrf2 pathway, a cellular defense system that increases antioxidant enzymes. Strengthening antioxidant defenses reduces oxidative damage and indirectly weakens inflammatory signaling, creating another route by which Ashwagandha can lower inflammation.

Most of what we know about these mechanisms comes from cell and animal studies; those experiments consistently show effects on NF-κB, MAPK, cytokines and inflammatory enzymes. Human trials are fewer and use different extract types and doses, but several clinical studies and reviews report reductions in blood markers of inflammation (for example C-reactive protein) and improvements in symptoms related to chronic inflammation. Because study methods and supplement quality vary, the human evidence is promising but not uniform.

It’s important to be cautious: “natural” does not guarantee safety or consistent effect for everyone. Ashwagandha can interact with medications and cause side effects in some people, and different supplements contain different amounts of active withanolides, so results will vary between products. Anyone considering Ashwagandha for inflammatory issues should discuss it with a healthcare professional and use a reputable product.

In short, Ashwagandha contains withanolides that can dial down central inflammatory switches (like NF-κB and MAPK), reduce inflammatory cytokines and enzymes, and boost antioxidant defenses; together these actions help explain why the plant can have anti-inflammatory effects, according to laboratory, animal and some human studies.

(Source : ChatGPT)

There is reasonable clinical evidence that ashwagandha (Withania somnifera) can provide real health benefits for some people, but the effects are usually modest, depend on the extract and dose, and are not miraculous or guaranteed for everyone.

The strongest and most consistent finding from human trials is that ashwagandha can reduce perceived stress and symptoms of anxiety and lower levels of the stress hormone cortisol. Several randomized, double-blind, placebo-controlled trials found that people taking standardized root extracts reported less stress and anxiety and showed reductions in morning cortisol, and researchers think part of the effect comes from modulation of the hypothalamic–pituitary–adrenal (HPA) axis. (PubMed)

Closely related to the stress results, a number of studies also report improvements in sleep quality and sleep onset in people who take ashwagandha for several weeks. Most clinical trials used standardized root extracts in the roughly 250–600 mg/day range and tested them for 6–12 weeks; pooled analyses and health-agency summaries describe modest but measurable benefits for sleep in adults with either insomnia or sleep complaints. (Bureau des Suppléments Alimentaires)

Beyond stress and sleep, growing—but still not definitive—evidence suggests ashwagandha may help with certain aspects of physical performance, body composition, and reproductive health in men. Small randomized trials and recent narrative reviews have reported modest increases in muscle strength and recovery when ashwagandha is combined with resistance training, small improvements in body-fat percentage, and in some trials improvements in sperm parameters and testosterone in men with low baseline values. These findings look promising but vary with the specific extract used, the population studied, and study quality, so they’re encouraging rather than conclusive. (PMC)

Why might it work? The herb contains steroidal lactones called withanolides plus other compounds that have anti-inflammatory, antioxidant and neuromodulatory actions in laboratory studies. Those activities map onto the clinical signals we see: lowering oxidative stress and inflammation can protect cells and brain function, while modulation of stress pathways (HPA axis) and neurotransmitter systems can reduce anxiety and improve sleep. In short, a combination of hormonal (cortisol) modulation and direct cellular protective effects likely explains the observed benefits in humans. (PubMed)

Safety and caveats: ashwagandha is generally well tolerated in short-term trials, but it’s not risk-free. Reported side effects include mild gastrointestinal upset, drowsiness, and occasional headaches. Important safety warnings include avoiding ashwagandha during pregnancy (some data and regulatory reviews advise against it because of potential adverse effects on pregnancy) and caution for people taking medications for thyroid disease, blood pressure, diabetes, or sedatives because interactions are possible. Long-term safety data are still limited and product quality varies widely between brands, so choosing standardized, third-party tested products and discussing use with a clinician is sensible. (RIVM)

Bottom line: if your goal is to reduce stress or improve sleep, there is good evidence that a standardized ashwagandha root extract taken at commonly studied doses (roughly 250–600 mg/day) can help for many people; other effects (muscle, fertility, metabolic markers) show promise but need more and larger trials to be definitive. Always check with your healthcare provider before starting any supplement, especially if you’re pregnant, breastfeeding, have chronic medical conditions, or take prescription medications.

(Source : ChatGPT)

Tulsi, commonly called holy basil (Ocimum tenuiflorum), is a cornerstone of Ayurvedic medicine and has been used for centuries as a warming tea or extract to support general well-being, respiratory health, digestion, and resilience to stress. (PMC) Tulsi is often described as an adaptogen: modern clinical trials and randomized, placebo-controlled studies report that standardized tulsi extracts can reduce perceived stress, improve mood and sleep in people experiencing stress, and help the body adapt to physical and mental challenges. (PMC) Laboratory and animal research shows that tulsi contains multiple bioactive compounds (phenolics, flavonoids, and essential oils) that have antioxidant and anti-inflammatory actions; these properties help explain why tulsi is studied for conditions linked to oxidative stress and chronic inflammation. (PMC) In addition, there is evidence from both preclinical work and some human studies that tulsi has immunomodulatory and antimicrobial effects and may support metabolic health—helping to moderate blood sugar and lipid markers in some trials—though the strength of evidence varies by condition and extract used. (sciencedirect.com) Generally tulsi is well tolerated when taken short term, but clinicians advise caution because concentrated extracts can interact with prescription medicines (for example blood thinners, diabetes drugs, or sedatives), and safety in pregnancy and breastfeeding is not well established; product quality and standardization also vary, so it’s wise to choose reputable preparations and check with a healthcare professional before starting tulsi as a supplement. (Cleveland Clinic)

Strongest clinical findings :

Here’s a concise, plain-text summary of the strongest clinical findings about Tulsi (holy basil, Ocimum tenuiflorum), with the key caveats up front.

Clinical trials give the clearest support for Tulsi’s role as an adaptogen: several randomized, placebo-controlled studies report that standardized Tulsi extracts reduce perceived stress, blunt physiological stress responses and lower markers of chronic cortisol exposure, and can also improve subjective sleep quality in adults experiencing stress. One well-designed 8-week trial (Holixer® extract, 250 mg/day) found reduced self-reported stress, smaller stress responses after an acute stress challenge, and lower cumulative cortisol. (ResearchGate)

The next strongest body of clinical evidence concerns metabolic effects. A meta-analysis of randomized clinical trials found that Tulsi supplementation was associated with modest but consistent reductions in fasting blood glucose and improvements in lipid parameters (total cholesterol, LDL, triglycerides) in people with metabolic disturbances. Individual randomized trials also reported small improvements in cholesterol and triglyceride levels. These effects are promising for metabolic risk factors, but the magnitude is typically modest and varies between studies. (sciencedirect.com)

Beyond stress and metabolic markers, clinical and human observational data hint at immune-modulatory and antimicrobial benefits, and many lab/animal studies show antioxidant and anti-inflammatory activity that could underlie broader health effects. However, the human clinical evidence for these uses is much thinner and more heterogeneous than the evidence for stress and metabolic outcomes, so these remain areas of active research rather than established therapeutic uses. (PMC)

Safety data from trials and regulatory reviews indicate Tulsi is generally well tolerated in short-term use at doses studied in trials, with few serious adverse events reported. Important safety notes are that data in pregnancy and breastfeeding are insufficient (and some guidance recommends avoiding use during pregnancy), and concentrated extracts could theoretically interact with prescription drugs (for example glucose-lowering medicines or anticoagulants), so clinicians advise caution for people on these medications. A recent national risk assessment also highlights variability between products and the need for quality control in supplements. (Drugs.com)

Typical trial doses have varied: some positive cognitive/stress trials used single daily doses in the ~250–300 mg range of standardized extract, while other studies have used split dosing (for example ~125 mg twice daily) or somewhat higher daily totals in different formulations; because formulations and standardization differ, dose cannot be translated directly from one product to another without knowing the extract’s specification. Overall, most human trials use modest daily extract doses (low hundreds of mg) rather than gram-level whole-leaf intakes. (ResearchGate)

In short: the strongest and most reproducible clinical signals for Tulsi are modest reductions in perceived and physiological stress and small improvements in metabolic risk markers (glucose and lipids). The herb appears generally well tolerated short-term, but product variability, unclear safety in pregnancy, and possible drug interactions mean you should treat Tulsi like any active supplement — evaluate the specific product, stick to doses used in trials, and check with a healthcare professional if you take prescription medicines.

(Source : ChatGPT 1, 2)